Pre-mild cognitive impairment …

Neurobehavioral & Cognitive Disorders

Updated 10.15.2024
Released 11.12.2019
Expires For CME 10.15.2027

Pre-mild cognitive impairment

Authors: Linda A Hershey MD PhD FAAN FANA, Dee Wu PhD

See Contributor Disclosures

Editor: Howard S Kirshner MD

Pre-mild cognitive impairment

In This Article

Quick Link

Introduction

Overview

In this article, the authors provide an overview of the diagnostic concept of pre-mild cognitive impairment, or subjective cognitive decline, which is a self-reported state of cognitive decline that is a transition state between normal aging and mild cognitive impairment. The authors also discuss the differential diagnosis for pre-Alzheimer mild cognitive impairment; memory complaints can also be caused by other neurodegenerative diseases, as well as medications, psychiatric conditions, sleep disorders, and medical illnesses. They review the various clinical, behavioral, radiologic, and genetic factors that are useful in predicting which cognitively normal older individuals will eventually go on to develop pre-mild cognitive impairment and dementia and discuss prevention and management techniques to slow this progression.

Key points

	• The pre-mild cognitive impairment stage of Alzheimer disease (subjective cognitive decline) is present when there are subtle symptoms of cognitive decline, but when the patient’s clinical signs of cognitive impairment are still insufficient to meet criteria for mild cognitive impairment. Mild behavioral impairment (affective dysregulation, poor impulse control, or decreased motivation) is more prevalent among those with mild cognitive impairment than among those with subjective cognitive decline.
	• The presence of subjective cognitive decline is not always sufficient to diagnose pre-Alzheimer mild cognitive impairment because other types of dementia and dementia mimics (medications, sleep disorders, psychiatric and medical conditions) can produce memory loss and other cognitive symptoms.
	• The imaging biomarker that best predicts transition from pre-mild cognitive impairment to mild cognitive impairment is abnormal amyloid PET, and the one that predicts transition from mild cognitive impairment to Alzheimer disease is abnormal tau PET. MRI features that best predict the transition to mild cognitive impairment are reduced hippocampal volume and any microhemorrhages, regardless of location. In a cognitively unimpaired older adult, the plasma biomarkers that best predict Alzheimer disease dementia within the first 6 years are p-tau 181, p-tau 217, and the APOE-4 allelic carrier status.
	• Longitudinal studies have shown that patients who have subjective cognitive decline or pre-mild cognitive impairment progress cognitively and functionally to mild cognitive impairment or dementia at a rate of about 7% per year. The rate of progression can be slowed with diet, exercise, as well as social, medical, and cognitive interventions.
	• Patients with pre-mild cognitive impairment progress faster to mild cognitive impairment than those who have no cognitive impairment at all, yet the rate of progression is slower than that seen when mild cognitive impairment progresses to dementia. Having more years of education and living in a more advantaged neighborhood increases cognitive reserve (slower decline in cognitive scores over time) and brain reserve (less cortical thinning).

Historical note and terminology

Subjective cognitive decline. This is the term used to describe subjective symptoms of memory loss or other cognitive changes that precede mild cognitive impairment or dementia. In 1982, Reisberg and others developed the 7-point global deterioration scale (GDS) for the description of progression from normal old age (GDS=0) to end-stage Alzheimer disease (GDS=7) (96). This scale included two stages (GDS=1 and GDS=2) that preceded mild cognitive impairment (GDS=3). Subjects with GDS stage 1 had subjective cognitive symptoms but no objective signs of cognitive decline whereas those with stage two had symptoms and subtle signs of cognitive decline.

Amnestic pre-mild cognitive impairment. In 2008, Caselli and colleagues were performing a longitudinal study on a group of healthy apolipoprotein E epsilon 4 (APOE-e4) carriers when they noticed an accelerated cognitive decline among those who appeared to be in a transitional state between normal aging and mild cognitive impairment (16). They identified these patients as having amnestic pre-mild cognitive impairment because their cognition declined more rapidly than normal controls but more slowly than those with mild cognitive impairment. In 2012, Loewenstein and others divided pre-mild cognitive impairment patients into three groups: (1) amnestic pre-mild cognitive impairment-NP patients who had impairment at 1.5 SD or more on one of three memory measures; (2) amnestic pre-mild cognitive impairment NP+ patients who had impairment at 1.5 SD or more on two or three memory measures; and (3) pre-mild cognitive impairment-clinical patients who had normal cognitive results on all memory and nonmemory cognitive measures, even though they had subjective complaints (63).

Predementia Alzheimer disease. In 2013, data from the Einstein Aging Study were used to prospectively evaluate the free recall score from the free and cued selective reminding test and the logical memory immediate recall subtest of the Wechsler memory scale-revised for prediction of incident Alzheimer disease dementia among a community-based cohort of 854 older individuals (> 70 years) who had memory complaints but no dementia (24). After 2 to 4 years, they found that the free recall score had better operating characteristics than the logical memory score in predicting which of the predementia patients would develop Alzheimer disease. APOE-e4 status improved positive predictive value but it did not affect the choice of optimal cut points.

Preclinical Alzheimer disease. In 2013, 145 cognitively normal individuals over 45 years of age were recruited from a longitudinal study of adult children of Alzheimer disease patients or normal elderly adults (54). Amyloid status was assessed with CSF measurement of amyloid-beta 42 levels (22.5% of the participants were amyloid positive). The amyloid positive group showed worse sleep quality than the amyloid negative group. In 2009, 183 Pittsburgh participants older than 80 years from the Ginkgo biloba Memory Study (145 normal; 38 MCI) were tested with amyloid PET and MRI at baseline. When they were re-examined five years later, 33% had developed dementia, and the best predictors were low hippocampal volume, high white matter hyperintensity volume, and the deposition of amyloid-beta on PET (64). In 2019, 1425 cognitively healthy controls from three large prospective studies were tested at baseline with amyloid PET or CSF amyloid-beta 42 levels. Those with preclinical Alzheimer disease (positive amyloid PET or CSF beta-amyloid) progressed cognitively over an average of six years to meet clinical criteria for mild cognitive impairment (48). In 2022, results from 461 cognitively unimpaired controls were reported from the BioFINDER study (88). Those who developed Alzheimer disease dementia within six years were more likely to have had elevated plasma levels of p-tau 181 at baseline. In 2023, 91 cognitively normal adults were followed in the Harvard Aging Brain Study (93). Those who developed Alzheimer disease after 4.6 years were more likely to have lower novelty-related locus coeruleus function with entorhinal tau deposition on tau-PET and elevated amyloid levels on amyloid-PET.

Resistance and resilience in Alzheimer disease. About 30% of people remain cognitively normal throughout their lifetime, even though at autopsy they have signs of Alzheimer disease (03). “Resilience” is the term used when cognitive symptoms are less severe than would be expected, given the pathology that is present (this “cognitive reserve” can often be explained by a patient’s higher level of education, their consumption of a healthy diet, their participation in regular exercise, or avoidance of cardiovascular risk factors, etc.). Higher cognitive reserve has been shown to attenuate the genetic risk of Alzheimer disease dementia (91). “Resistance” is the term used when amyloid or tau levels are less than would be expected, given the patient’s family history, etc. For example, there is an Icelandic sequence variation in the APP gene that confers protection against the onset and progression of Alzheimer disease (38). Education may have opposite effects, depending upon the stage of Alzheimer disease that is being considered. In preclinical stages, for example, those who have higher levels of education may be more aware of their memory deficits and may express more subjective cognitive complaints, but have lower amyloid or tau burden (showing resistance). In the clinical stage of Alzheimer disease, higher education appears to attenuate symptom severity (supporting the idea of cognitive resilience) (11; 44). Another factor contributing to cognitive resilience in later life is the complexity of one’s occupation in midlife. For example, those with jobs associated with routine repetitive tasks (cleaners, store clerks, etc.) have been shown to be at higher risk of mild cognitive impairment and dementia after 30 years, compared to those who had fewer repetitive job tasks (nurses, teachers, etc.) (28).

Clinical manifestations

Presentation and course

Subjective cognitive decline. Patients with pre-mild cognitive impairment and subjective cognitive decline usually complain of memory loss, but some might notice problems with other cognitive domains such as organizational skills, language, or visuospatial function (126; 115). The term “subjective” implies that validation of the subjective experience is not needed on a cognitive test. In the context of establishing the diagnosis of pre-mild cognitive impairment, it is important that cognitive testing is performed to exclude cases of true mild cognitive impairment (126). Patients with subjective cognitive decline often exhibit symptoms of mild behavioral impairment (with affective or psychotic symptoms) in addition to their cognitive complaints (104; 115). In one study, the strongest predictor for subjective memory complaints was depressed mood, whereas reduced hippocampal thickness was associated with objective memory impairment but not subjective complaints (62).

Age of onset. Most studies of subjective cognitive decline unrelated to the autosomal dominant type of Alzheimer disease restrict the age of symptom onset to 60 years or older. Including younger ages of onset increases the risk of enrolling too many cases that will go on to develop non-Alzheimer types of dementia.

Sex preponderance. More women than men have Alzheimer disease, but in a metaanalysis of 56 different studies, there were no significant sex differences in the incidence or prevalence of amnestic mild cognitive impairment (04). In one multimodality brain imaging study, cognitively normal older women and men were compared with respect to sex-based differences in brain biomarkers; women were shown to develop the Alzheimer phenotype earlier than men with higher beta-amyloid accumulation and lower levels of glucose metabolism (95).

Racial disparities. Several studies have shown higher incidence rates for Alzheimer disease among African Americans than for white Americans. A meta-analysis demonstrated that the Alzheimer incidence rate for African Americans was 64% higher than for Caucasians (110). The authors concluded that the reasons for these disparities in incidence rates were unknown but may include both biological and socioeconomic factors. A longitudinal study based in Chicago also demonstrated higher incidence rates for Alzheimer disease among black Americans, compared to white Americans (123). Similar racial disparities were also observed when subjective cognitive decline patients were followed over 20 years in a multiracial community sample in New York City (18).

Studies have demonstrated racial disparities in molecular biomarkers for Alzheimer disease, especially in the prodromal stages, such as in patients with pre-mild cognitive impairment. At the Knight Alzheimer Research Center in St. Louis, for example, a total of 1255 participants (173 African Americans) were enrolled in biomarker studies from 2004 to 2015 (80). These authors found that in participants with a positive family history of dementia, hippocampal volumes were lower in African Americans, compared to White participants. Mean CSF concentrations of total tau and p-tau were also lower in African Americans, even when data were adjusted for sex, educational level, and APOE-e4 status. These findings of lower levels of CSF tau-based biomarkers in African Americans with prodromal Alzheimer disease were replicated in a case-control study from Emory University in Atlanta (33).

In the Atherosclerosis Risk in Communities (ARIC) study, analyses of Black American participants showed associations between the presence of ventricular arrhythmias and dementia, whereas no such associations were found among white participants (84). Another observation that helps to explain racial disparities is that living in a disadvantaged neighborhood appears to have an effect on accelerated degeneration of the brain in signature regions that are affected by Alzheimer disease (45). Those living in disadvantaged neighborhoods in later life are also less likely to perform well on standard cognitive tests.

Heredity. Cognitively normal older adults who carry at least one APOE-e4 allele are at higher risk for developing pre-mild cognitive impairment (and at an earlier age) than noncarriers. The APOE-e4 allele is the strongest genetic risk factor for late-onset Alzheimer disease. Those carrying the APOE-e4 allele (compared to those carrying e2 or e3) are more likely to progress more rapidly from the pre-mild cognitive impairment state to the Alzheimer dementia state (94).

Anosognosia. There is a subset of pre-dementia Alzheimer disease patients who have no subjective awareness of their cognitive decline in the very early stages of their illness. They represent a group with early anosognosia, or denial of cognitive deficits. When one group of investigators examined how awareness of diagnosis affected quality of life among older adults with mild cognitive impairment, they learned that those who were aware of their diagnosis had lower satisfaction with daily life and lower physical well-being than those who were unaware (111).

Prognosis and complications

Subjective cognitive decline. Several studies with subjective cognitive decline patients have shown that the rate of cognitive and functional decline is about 7% per year. When patients with global deterioration scale stage 2 (subjective cognitive decline with subtle cognitive impairment) were followed for seven years, they were 4.5 times more likely to progress compared to those with GDS stage 1 (no subjective or objective cognitive decline). The rate of decline in GDS scores was 6.7% per annum (97). Besides progression of GDS scores, these subjective cognitive decline patients also experienced decline in their global cognitive scores, remote memory scores, and functional/self-care scores. When subjective cognitive decline patients with and without depression were compared in an Austrian study, those with depression were shown to have more difficulties with activities of daily living than those without depression (112). When Chinese patients with subjective cognitive decline were divided into those with and without worry, those with worry were noted to have poorer sleep quality and reduced sleep efficiency, which was the reason put forward for their higher risk of developing Alzheimer disease (19). “Dementia worry” is a term that refers to the fear of developing dementia; it can have positive outcomes (patients may adopt more positive lifestyle habits), or it can have negative outcomes (patients may begin to underutilize the healthcare system or mistrust their providers) (76). In both Chinese and German cohorts of subjective cognitive decline participants, those who were amyloid positive showed steeper cognitive decline over 6 years compared to those who were amyloid negative (102).

Mild behavioral impairment. This is a construct describing the emergence in older adults (> 50) of neuropsychiatric symptoms that are precursors to cognitive decline and dementia. The symptoms of mild behavioral impairment must last at least six months, but not be severe enough to be captured into a traditional psychiatric diagnosis. There is a 34-item mild behavioral impairment checklist that can be completed by the patient, caregiver, or clinician (49). Older adults with subjective cognitive impairment experience increasing affective symptoms, reduced engagement in their usual activities, and lower quality of life than age-matched controls (43). Mild behavioral impairment is more prevalent among those with mild cognitive impairment (85.3%) than among those with subjective cognitive decline (76.5%) (104). Pre-mild cognitive impairment patients who have symptoms of mild behavioral impairment have a more rapid decline in attention and working memory, suggesting that mild behavioral impairment might be a novel target for dementia clinical trials (21). Other investigators have shown that baseline neuropsychiatric inventory anxiety scores are associated with decline in recall on the symbol digit memory task over a period of 5.7 years (13). Baseline neuropsychiatric inventory total scores are associated with a more rapid rate of decline on word list memory, praxis recall, and animal frequency tasks among clinically normal older adults and are predictors for pre-mild cognitive impairment. Studies of Alzheimer biomarkers have shown that plasma levels of p-tau 181 are higher in dementia-free patients with mild behavioral impairment than in similarly aged older adults who have no neuropsychiatric symptoms (34).

Clinical vignette

Case. This 62-year-old woman was referred for memory problems, anxiety, and insomnia for the last eight months. The memory problems began when she started taking steroids for sudden onset of hearing loss in her right ear, but they persisted after she stopped taking the steroids a month later. She had an MRI scan for the hearing loss, but it showed no signs of stroke, hydrocephalus, or hippocampal atrophy. She had a family history of dementia (her mother died at age 85 of Alzheimer disease). She lived on her own and denied functional impairment in performing everyday tasks. Her other medications included lorazepam 1 mg bid and citalopram 20 mg/d for anxiety and diphenhydramine 50 mg qhs for insomnia. She scored 28 out of 30 (normal range) on the Mini-Mental State Examination, losing 2 points on attention tasks. The rest of her neurologic examination was unremarkable. Her complete blood count, lipid panel, and blood chemistries showed no signs of anemia, diabetes, or renal or liver disease.

Advice. This patient was advised to stop the diphenhydramine and to start trazodone 50 mg qhs. The dose of trazodone was eventually moved up to 100 mg qhs because it helped her with both anxiety and insomnia. Diphenhydramine has both anticholinergic and antihistaminergic properties and is known to worsen memory complaints, so it needs to be stopped in those who have symptoms of pre-mild cognitive impairment (36). She was advised to walk for 30 minutes a day and to eat a Mediterranean diet to prevent further progression of her memory problems. Exercise and diet have been shown to slow progression along the continuum from healthy aging to Alzheimer disease (83; 100; 26; 131; 01).

Biological basis

Genetic risk factors for Alzheimer disease. First-degree relatives of patients with Alzheimer disease are at increased risk for developing the disease themselves (RR=1.73) (14). Older adults who carry at least one APOE-e4 allele are at higher risk for memory decline to the pre-mild cognitive impairment state compared to noncarriers. The APOE-e4 allele is the strongest genetic risk factor for late-onset Alzheimer disease. APOE-e4 carriers have been observed to have increased accumulation of beta-amyloid in the brain, but this phenomenon has been shown to be attenuated in those who are heterozygous for the KLOTHO gene variant KL-VS (29). The APOE genotype contributes to the heterogeneity in the rate of transition from pre-mild cognitive impairment to Alzheimer dementia as MMSE scores in those carrying the APOE-e4 allele have been noted to fall faster than in those carrying APOE-e2 or e3 alleles (94). New data suggest that the blood brain barrier is affected by the APOE genotype (05). In APOE-e4 mice (compared to e2 or e3 mice), basement membrane thickness is reduced as a function of decreased phosphorylation of occludin (an enzyme that oxidizes NADH) and decreased levels of collagen IV. The APOE genotype has an influence on the obesity paradox in dementia (107). Obesity was noted to be associated with more cognitive decline in cognitively normal older individuals without the APOE-e4 allele, especially in those with the APOE-e2 allele (these patients have more microinfarcts), but obesity is also associated with less cognitive impairment among those with mild cognitive impairment, especially those who carry the APOE-e4 allele. This is called the obesity paradox. Other gene loci have been identified as being risk factors for Alzheimer disease, including those involved in the amyloid and tau pathways (08). Even more genetic factors contribute to Alzheimer risk if they have an influence on immune activation, abnormal protein aggregation, abnormal cytoskeleton formation, altered energy homeostasis, and inflammation (125; 65).

Imaging and CSF biomarkers for Alzheimer disease. In pre-mild cognitive impairment and subjective cognitive decline, several neuroimaging and CSF biomarkers for Alzheimer disease become abnormal before patients develop clinical symptoms of dementia. In the Baltimore Longitudinal Study of Aging, 171 cognitively normal participants 56 to 95 years of age had neuroimaging to measure mean cortical amyloid levels and MRI to assess hippocampal volume (09). Those with signs of amyloidosis or hippocampal atrophy were more likely to experience cognitive progression over time, even though they met criteria for being in the preclinical stages of Alzheimer disease. This was also true in the Ginkgo biloba Memory Study because several of the cognitively normal older participants (over 80 years) had abnormal amyloid PET scans at baseline in that clinical trial (64). In the Swedish Bio FINDER study, for example, increased isotope uptake on tau PET scans was associated with worse clinical performance on a variety of cognitive tests in those who began with pre-mild cognitive impairment (87). These findings were similar to those of the large (n=1343) Mayo Clinic study, where abnormal amyloid PET scans appeared during the pre-mild cognitive impairment stage of pre-Alzheimer disease, but tau PET scans did not become abnormal until patients developed signs of dementia (51). In a smaller longitudinal study of 60 clinically normal participants who were 73 years of age at study onset, Hanseeuw and others showed that an initial rise in amyloid burden on PET was usually followed by tau changes, then cognitive decline (40). Other investigators found in a large group (n=814) of cognitively normal older individuals that three CSF biomarkers were significantly associated with greater cognitive decline after seven years, compared to those who were free of abnormal biomarkers (beta-amyloid, phosphorylated-tau, and total-tau) at baseline (109). These findings supported earlier observations demonstrating the clinical utility of the Erlangen score algorithm as a useful tool in identifying predementia subjects in two large longitudinal study cohorts (the U.S. Alzheimer’s Disease Neuroimaging Initiative and the German Dementia Competence Network) (60). In that algorithm, if CSF beta-amyloid or tau were abnormal, then Alzheimer disease was a possible or probable future diagnosis. Wolfsgruber and colleagues showed that patients with subjective cognitive decline had worse performance on tests of global cognition, as well as lower concentrations of CSF beta-amyloid 42/40 and beta-amyloid 42/p-tau 181 (126). Spatial extent-based measures for how amyloid is spread throughout the cortex in amyloid-PET scans have been shown to be more sensitive than level-based measures in preclinical Alzheimer patients (30). These extent-based measures improved prediction of cognitive decline, as well as tau proliferation, compared to level-based measures alone.

Imaging and plasma biomarkers for Alzheimer disease. In France, older adults with subjective cognitive decline (n=276) were recruited into a longitudinal study of plasma biomarkers and neuroimaging (17). Cavedo and colleagues found that plasma concentrations of total tau were associated with faster rates of brain atrophy in the basal forebrain. This association was independent of the patient’s beta-amyloid status and APOE genotype. In the Mayo Clinic Study of Aging (n=1343), participants who were recruited were either cognitively unimpaired, had mild cognitive impairment, or had probable dementia (51). The authors learned from this study that a positive amyloid PET scan could be associated with normal cognition, whereas an abnormal tau PET scan was never associated with a cognitively unimpaired person. In the EPAD cohort and ADNI study, plasma levels of p-tau 181 were increased in the preclinical stages of Alzheimer disease, and they increased further when patients reached the mild cognitive impairment stage (46; 55). In the BioFINDER study, plasma levels of both p-tau 181 and A-beta 42/40 were both good predictors for Alzheimer dementia within six years in those who had mild cognitive impairment at baseline (88). Of these biomarkers, plasma p-tau 181 has emerged as the most sensitive and specific to detect Alzheimer disease in older adults (02).

Imaging risks for mild cognitive impairment and dementia. In the United States, older adults with unimpaired cognition (n=1553) were followed in a multicenter longitudinal imaging study (127). The MRI factors that increased the risk of developing mild cognitive impairment were decreased hippocampal volume (HR=1.27) and any microhemorrhages (HR=1.79). Lacunar infarcts increased the risk for dementia (HR=1.66), as did higher volume of white matter hyperintensities (HR=1.44) and lobar microhemorrhages (HR=1.90). In a French study of 318 older adults with subjective memory complaints and a mean age of 76, the mean MMSE score at baseline was 28.7 (27). Four participants (all positive for amyloid-PET at baseline) progressed to prodromal Alzheimer disease (they were more likely to be older, to have more highly positive PET scans, and to be carriers of the APOE-e4 allele).

Etiology and pathogenesis

Neurodegeneration. In most cases of pre-mild cognitive impairment, the etiology is presumed to be neurodegeneration due to early Alzheimer disease (51; 87). In patients who were imaged in various stages of the Alzheimer disease continuum, the accumulation of amyloid (on amyloid-PET) was shown to occur in the pre-MCI stage of Alzheimer disease (50). This preceded the deposition of tau (on tau-PET) and the development of neurodegeneration on MRI. In a large longitudinal study (n=1843), patients with cognitive complaints about one year prior to autopsy were classified according to no complaint, self-only, informant-only, or mutual (both self and informant) complaint. The mutual complaint group had higher odds (OR=5.82) of having autopsy evidence of Alzheimer disease (35). Longitudinal imaging studies with tau PET have shown that baseline tau uptake patterns map better onto the clinical phenotype of Alzheimer disease than longitudinal tau uptake patterns, supporting the important causal role of tau as a driver of clinical dysfunction in Alzheimer disease (108; 120).

Neuroinflammation. Alzheimer disease is also associated with neuroinflammation as well as cerebrovascular changes. The authors of the Swedish Bio FINDER cohort followed 256 patients with mild cognitive impairment, 57 with Alzheimer dementia, and 508 cognitively unimpaired elderly persons for about six years, monitoring 11 neuroinflammatory and cerebrovascular biomarkers, as well as conventional biomarkers of Alzheimer disease (52). They found that elevated levels of five inflammatory and cerebrovascular biomarkers were associated with Alzheimer pathology. Neuroinflammatory biomarkers were detected in the pre-mild cognitive impairment stage, as well as the mild cognitive impairment and dementia stage of Alzheimer disease.

Blood-brain barrier breakdown. Animal studies have suggested that both amyloid and tau can lead to blood vessel abnormalities and blood brain barrier breakdown. Nation and others examined capillary damage in humans who were in the early stages of cognitive dysfunction on the Alzheimer continuum (81). They showed evidence of blood brain barrier breakdown in the hippocampus that was independent of levels of amyloid or tau. Montagne and others demonstrated that participants bearing the APOE-e4 allele (either ¾ or 4/4 individuals) could be distinguished from APOE-e3/3 participants by their having breakdown in the blood brain barrier in the hippocampi and medial temporal lobes (78). This finding was measurable in cognitively unimpaired APOE-e4 carriers, but it was more severe in those who had cognitive impairment. As with the study of Nation and colleagues, their findings appeared to be independent of amyloid or tau pathology in CSF or PET (81).

Aortic stiffness. In the Vanderbilt Memory and Aging Project, data on aortic stiffness, biomarkers of neuroinflammation, and Alzheimer biomarkers were collected from 146 stroke-free and dementia-free participants (79). Among those who were 74 years of age and older, greater aortic stiffness was associated with biomarkers of neuroinflammation, phosphorylated tau, synaptic dysfunction, and neurodegeneration, but not with amyloidosis. The authors proposed that neuroinflammation and synaptic dysfunction might be the common two pathways by which aortic stiffness exerted its injurious effects on the brain.

Intermittent hypoxia. In a 2-year prospective longitudinal study of nondepressed healthy older adults, the severity of obstructive sleep apnea was shown to be associated with the annual rate of change in CSF beta-amyloid indices after adjustment for age, sex, BMI, and APOE-e4 (103). The authors attributed the mechanism to be due to either sleep fragmentation or to intermittent hypoxia.

Epidemiology

Progression from pre-mild cognitive impairment to mild cognitive impairment or dementia. Pre-mild cognitive impairment patients with clinical complaints but no neuropsychological deficits were observed to progress to mild cognitive impairment or dementia at a rate of 22% over a period of 2 to 3 years, compared to a rate of 3.7% in an age-matched group of normal controls (63). The progression rate was faster (38.9%) in those who also had objective neuropsychological deficits in one or more memory measure. Progression was best predicted by the baseline performance on certain cognitive tests (at least two memory domains). When a meta-analysis was performed of studies of older individuals with and without subjective memory complaints, the annual risk of developing mild cognitive impairment in those with memory complaints was 6.67% (75). In a systematic review and meta-analysis, Rostamzadeh and colleagues screened eight observational studies of patients with subjective cognitive decline to find which fluid biomarkers of Alzheimer pathology would best predict conversion to mild cognitive impairment or dementia (99). They found that after a mean of 3.3 years, the best predictors were those of the full Alzheimer profile (both amyloid and p-tau pathology).

Progression from healthy control to mild cognitive impairment. The time required for clinically meaningful cognitive decline in amyloid positive patients with normal cognition at baseline to mild cognitive impairment was about six years (48). The amyloid positive patients had abnormal amyloid PET scans or positive results on CSF studies. This study was done to determine that a clinical trial with a preventive agent in pre-clinical Alzheimer patients would need 2000 subjects at baseline to achieve 80% power in a 4-year trial to see a treatment effect size of 25%. Van Dyck and others enrolled a somewhat smaller number of mild cognitive impairment or mild Alzheimer dementia patients into the lecanemab (n=898) and placebo (n=897) arms of their clinical trial (118). By the end of 18 weeks, they found 27% slowing in the severity of disease progression among those treated with lecanemab, compared to those assigned to placebo.

Progression from healthy control to Alzheimer dementia. In the Pittsburgh participants from the Ginkgo biloba Memory Study, the time required to decline from normal cognition (n=145) to dementia (n=60) among a group of older than 80-year-old participants was about five years (64). The time required for significant cognitive decline in two groups (65 years and older) of African Americans and non-Hispanic whites in Chicago was about six years (26). After that period of time, 20.5% to 24.9% had developed Alzheimer dementia. In a national multiethnic longitudinal study (Health and Retirement study), the risk for dementia by age 76 was 10%, whereas the risk for mild cognitive impairment was 22% (68). In a group of European mild cognitive impairment patients (mean age = 68 years), the speed of conversion to dementia was faster (about 1 year) if all three core Alzheimer disease biomarkers were positive (CSF amyloid-beta42, FDG-PET, and hippocampal atrophy), compared to the speed of conversion (about 2 years) if only the amyloid biomarker was positive (92). A large group of Chinese individuals (n=648) was followed with CSF biomarkers, brain imaging, and cognitive tests for 20 years prior to the onset of Alzheimer dementia (53). At 18 years prior to the diagnosis of Alzheimer dementia, the only CSF biomarker to be recognized as abnormal was A-beta 42. This was followed at about 11 years by abnormal levels of CSF p-tau 181, then at 9 years by loss of hippocampal volume. Finally, about 6 years prior to the dementia diagnosis, cognitive symptoms and signs were recognized (mild cognitive impairment).

Prevention

Diet. Current alcohol use was associated with reduced risk of progression to incident dementia in those younger than 87 years (32). Moderate adherence to the MIND and the Mediterranean diets may also reduce Alzheimer risk (26; 01). In one randomized controlled trial of older adults who were not yet cognitively impaired (but who had a family history of dementia), the MIND diet with mild caloric restriction improved cognitive scores after three years to a similar extent as the control diet with mild caloric restriction (07). It is important to note that enrollment criteria for this study included a BMI greater than 25 and a baseline “suboptimal diet”, as determined by a 14-item questionnaire. This trial is likely to have been under-powered to detect cognitive differences between the two treatment groups at three years, since only 301 participants were assigned to the MIND diet, and 303 to the control diet. The cognitive risk of certain BMI values can have different outcomes, depending upon gender and environmental setting. For example, low BMI values in older Chinese women were associated with higher risk of developing mild cognitive impairment, wheras high BMI values were related to elevated risk in older Chinese men (130). These findings from rural Chinese study participants differed from Singapore residents who lived in an urban setting, where both older men and women with the metabolic syndrome experienced an increased incidence of mild cognitive impairment (82).

Exercise. Physical activity in older adults may improve cognitive reserve so that the brain can better withstand various neurodegenerative and vascular insults. A meta-analysis of 19 exercise studies comparing exercise with nonexercise control groups (1145 subjects with a mean of 77 years) concluded that exercise training may delay the decline in cognitive function that occurs in individuals at risk of Alzheimer disease, with aerobic exercise being the most effective intervention (90). The Rush Memory and Aging Project reviewed data from 454 decedents in the Chicago area who had had actigraphic data; they showed that higher total daily physical activity was independently associated with better global cognitive scores (12). A meta-analysis of 41 exercise intervention studies demonstrated that adherence to exercise interventions in older people with mild cognitive impairment can be limited by adverse events, such as mild joint pain, injuries, and falls (25). In a prospective examination of 501,376 nondemented United Kingdom Biobank participants, 5185 cases of dementia were identified at 10.7 years (131). Frequent engagement in exercise (household-related activity or leisure-time activity) was shown to be associated with reduced risk of dementia at 10.7 years (HR=0.65). In the Southern Community Cohort Study of 17,209 nondemented older persons, 1694 cases of dementia were identified over a median period of four years (129). Engaging in greater than 150 minutes of moderate exercise per week was shown to reduce the risk of all-cause dementia (HR=0.89). This beneficial effect was found to persist regardless of age, sex, race, or income level.

Cognitive reserve and brain reserve. Compared to those in the predementia stages, those with dementia have less education and a greater amount of baseline cerebral atrophy (37). This study suggested that educational levels provided a proxy for cognitive reserve (slowing the development of cognitive decline), whereas intracranial volume as measured by MRI was a proxy for brain reserve (slowing the thinning of cortical areas involved in Alzheimer disease). In a nation-wide longitudinal study of aging (Health and Retirement study), investigators found that each year of education produced a measurable decrease in the risk of both dementia and mild cognitive impairment (68). Living in an advantaged neighborhood proved to be another factor that was correlated with both cognitive reserve and brain reserve (45). Those who live in better neighborhoods are less likely to have cognitive decline in their later years, and they also have less cortical thinning in areas of the brain that are affected early on by Alzheimer disease.

Multidomain interventions. In Europe, a multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring was shown to produce a small amount of cognitive improvement at the end of two years (n=631), compared to a control intervention (n=629) in an at-risk elderly population (83). In the United States, a multidomain intervention study has been designed for those who are at various stages of cognitive impairment, including mild dementia, mild cognitive impairment, and subjective cognitive decline (100). The intervention consists of weekly phone calls and three visits with the patients’ “health care champion” to reinforce adherence to the Mediterranean diet, regular physical activity, and cognitive activity. A United States randomized trial of aerobic exercise and the DASH diet in 160 sedentary older men and women who had cognitive impairment with no dementia (CIND) demonstrated that those assigned to the aerobic exercise arm (with no dietary change) experienced significant improvement in executive function (10). The largest cognitive improvements, however, were seen in those assigned to the exercise plus diet arm of the study. Multidomain intervention has also been demonstrated to be beneficial in two other United States studies, where those who adhered to at least four of five lifestyle changes had a 60% reduction of Alzheimer risk (at least 150 min/wk of moderate exercise, smoking avoidance, light-moderate alcohol intake, MIND diet, and cognitive activities) (26). The Lancet Commission added three new modifiable risk factors to the “standard” list of nine modifiable risk factors for dementia (poor education, hypertension, hearing impairment, smoking, obesity, depression, physical inactivity, diabetes, and insufficient social contact). The “new” risk factors added by the Lancet Commission are excessive alcohol consumption, traumatic brain injury, and air pollution (61).

Controlling blood pressure. Elevated blood pressure (> 140/90) during midlife and the persistence of high blood pressure into late life have both been associated with an increased risk of incident dementia in a community-based cohort (69). The risk of dementia increased with increasing systolic blood pressure, with an additional 20% increase in risk for every 10 mm Hg increment in midlife systolic blood pressure. Persistence of high blood pressure into late life results in a 25% increase in risk of dementia above the risk attributable to midlife hypertension alone. The SPRINT MIND Research Group conducted a randomized clinical trial at 102 sites among those over 50 years of age with hypertension, but without diabetes or stroke, with the aim of reducing mild cognitive impairment and dementia (124). They showed that intensive blood pressure control (systolic less than 120 mm), compared to standard control (systolic less than 140 mm), significantly reduced the risk of mild cognitive impairment (HR=0.81; p=0.007), but there was no significant difference for probable dementia.

Avoiding air pollution/exposure to building collapse situations. Long-term exposure to ambient air pollution is known to be associated with increased risk of cardiovascular disease and stroke (57). Studies have shown that long-term exposure to air pollution in urban areas (especially nitrogen dioxide and fine particulate matter) is also a risk factor for cognitive decline (56; 61). A prospective cohort study examined 5010 World Trade Center responders (mean age was 53 in 2001) to compare the incidence of new-onset dementia among those who sustained severe exposure to building dust and debris, compared to those who were not exposed (or who wore personal protective equipment) (20). Those who had severe exposure were more likely to develop new-onset dementia after 15,913 person-years of follow-up. The authors’ conclusion was to recommend mandatory use of personal protective equipment for workers who are involved in clean-up during exposure to building collapse situations.

Avoiding anticholinergic medications. Risk factors for mild cognitive impairment were investigated in 688 cognitively normal participants in the Alzheimer Disease Neuroimaging Initiative (ADNI) who were 73.5 years of age at baseline and were followed for over 10 years (122). Those who were chronically taking drugs with anticholinergic activity had increased risk for progression to mild cognitive impairment (HR=1.47); those who were taking anticholinergic drugs and carried an APOE-e4 allele showed even greater risk (HR=2.69).

Avoiding disruptive sleep habits. In the A4 study of cognitively unimpaired older adults, data were collected on sleep duration and amyloid PET on 4425 participants (mean age was 71.3 years) (47). Each additional hour of nighttime sleep was shown to be associated with reduced global amyloid uptake on PET. Daytime sleep could not compensate for loss of nighttime sleep in terms of the protection that sleep offered with respect to the accumulation of brain amyloid. Obstructive sleep apnea is a potential modifiable risk factor for cognitive disorders in the elderly (103; 06; 47). Positive airway pressure has been demonstrated to be associated with a lower incidence of cognitive disorders and cognitive decline among adults who have obstructive sleep apnea (106).

Differential diagnosis

Confusing conditions

Anticholinergic medications. Impaired cognition is a known risk of using anticholinergic medications, especially in those who are over the age of 65 years. In a large cohort study of the elderly (n=3434) with a mean follow-up of 7.3 years, 797 participants developed dementia; higher cumulative anticholinergic use was associated with an increased risk of dementia (36). When we hear our patients telling us about memory complaints, we must be sure to discontinue antihistamines, gastrointestinal antispasmodic agents, antivertigo agents, bladder antimuscarinic drugs, and antidepressants with anticholinergic effects.

Ischemic amnesia. Amnesia as the main complaint of an ischemic event is rare, and it can be difficult to distinguish ischemic amnesia from transient global amnesia (73). Most amnestic strokes are cardioembolic in origin, involving multiple territories, including the posterior circulation and the limbic system. About a third of amnestic stroke patients have persistent memory problems.

Associated or underlying disorders

Sleep disorders. Sleep-disordered breathing, characterized by recurrent arousals and intermittent hypoxemia, has been shown to be a prelude to cognitive impairment and accumulation of brain amyloid (54; 39; 06). In a large 5-year study of community-dwelling men and women, the presence of sleep-disordered breathing was associated with a younger age of onset of mild cognitive impairment (mean age = 72.6 years), compared to a group with no sleep disordered breathing (mean age = 83.7 years) (86). The link between poor sleep and Alzheimer disease has been demonstrated as an association between disruptions of non-REM slow wave sleep and CSF levels of beta-amyloid (67). This overexpression of CSF beta-amyloid with sleep disruption can be seen both in animal models of Alzheimer disease as well as in nondemented humans (103; 47).

Psychiatric conditions. Depression can be a factor associated with symptoms of pre-mild cognitive impairment and mild cognitive impairment. Among 183 mild cognitive impairment patients, the presence of significant depressive symptoms on the Cornell Scale for Depression in Dementia appeared to be a predictor of progression to Alzheimer disease (HR = 2.06) (117). Those who had signs of severe depression were excluded in this study. The mild behavioral impairment checklist is useful in separating patients with mild behavioral impairment from those who might have traditional psychiatric conditions (49). Mild behavioral impairment patients, for example, might have decreased motivation, but they may not score as high as someone with severe bipolar depressive disorder. Referral to geriatric psychiatry is always recommended whenever this distinction is in doubt. Late-onset psychosis and REM sleep behavior disorder may predate clinical signs of dementia by many years in patients with prodromal dementia with Lewy bodies (116).

Medical illnesses. Hearing and visual loss, as well as diabetes, anemia, and hepatic and renal failure, may all lead to symptoms similar to those of pre-mild cognitive impairment (82; 31; 61; 128). In a large study of elderly Stockholm residents, 5.8% developed dementia during a 5-year follow-up period (128). Those who had lower glomerular filtration rates had a greater likelihood of developing dementia. In the Atherosclerosis Risk in Communities Study, there was a higher rate of dementia among older adults who had evidence on ECG of ventricular arrhythmias than among controls (84). These factors need to be considered (and appropriate laboratory levels drawn and ECG performed) whenever pre-mild cognitive impairment patients are being evaluated for memory complaints.

Diagnostic workup

Medication history. It is important to take a thorough medication history in patients who have pre-mild cognitive impairment and discontinue or reduce the dose of drugs that have anticholinergic effects (31). These drugs can have serious cognitive effects, and in some cases, they can even lead to a diagnosis of dementia (36; 122).

Laboratory tests. Pre-mild cognitive impairment patients need a complete blood count to exclude anemia, complete chemistry panel to exclude renal and hepatic failure, vitamin B12 and D levels to exclude deficiencies in those vitamins, and thyroid stimulating hormone level to exclude hypothyroidism as a cause of memory loss (31).

Alzheimer disease biomarkers. Three pathologic processes are key to making an accurate diagnosis of Alzheimer disease: deposition of extracellular amyloid plaques, accumulation of intracellular tau-based neuro-fibrillary tangles, and evidence of neurocortical neurodegeneration. During the pre-mild cognitive impairment stage, many patients will be curious about their risk of Alzheimer disease and will request plasma or CSF tests of Alzheimer disease biomarkers (46; 99; 34; 53; 102). Recent guidelines have been published to help clinicians to determine: a) the appropriateness of CSF or plasma biomarker testing, b) what pretest educational/consent information to implement, and c) what follow-up procedures to use to best promote a person’s well-being (59). One commercially available blood test for Alzheimer disease calculated an amyloid probability score after measuring plasma amyloid-beta 42/40 ratio, APOE-e4, and age (02). The cost of this test in 2022 was $1250. The test cannot make the diagnosis of Alzheimer disease, but it can increase confidence that the patient has an increased number of amyloid plaques in the brain.

Magnetic resonance imaging (MRI). Most neurologists recommend an MRI for patients with pre-mild cognitive impairment to exclude treatable conditions such as tumor or hydrocephalus. In the Rotterdam Study (a large population-based longitudinal study with n=4198), investigators asked which MRI correlates were most likely to be associated with prognosis of mild cognitive impairment; they found that the best correlates were larger white matter lesion volume and higher prevalence of lacunes (23). Measurements of hippocampal volume have been used to predict which cognitively unimpaired individuals will be most likely to progress to mild cognitive impairment or dementia (64; 127). The combination of the Mini-Mental State Examination and hippocampal volume, normalized by the cerebellar volume, can distinguish which mild cognitive impairment patients will progress to Alzheimer disease within five years from those who will not progress (113). In the Atherosclerosis Risk in Communities Study, 1553 participants who were dementia-free at baseline were examined with MRI and then tested cognitively about five years later (127). The MRI features that best predicted the onset of mild cognitive impairment were reduced hippocampal volume (HR=1.27) and any microhemorrhages (HR=1.79). In the Mayo Clinic Study of Aging, cortical thickness on MRI was measured in 192 patients with various mild cognitive impairment subtypes and 1257 cognitively normal individuals (66). The subtle cognitive impairment cluster (pre-mild cognitive impairment patients) showed signs of atrophy in the entorhinal and parahippocampal cortices, whereas other mild cognitive impairment subtypes demonstrated atrophy in these areas and others, depending on their clinical presentation. In the Swedish National study on Aging and Care in Kungsholmen (SNAC-K), 436 cognitively normal elderly participants were imaged with MRI at baseline and followed at 3, 6, and 9 years (121). Incident dementia was found in 46 participants and was associated with the baseline microvascular lesion score (including lacunes, white matter hyperintensities, and perivascular spaces) as well as the neurodegeneration load (enlarged ventricles and reduced hippocampal volume). Advanced MRI techniques are capable of revealing the “cingulate island sign” that is pathognomonic for prodromal dementia with Lewy bodies (116). One group of investigators has argued for combining MRI with amyloid PET as a way to improve classification performance in older adults with cognitive impairment (98). When they examined MRI scans among 454 participants, they found that Alzheimer patients had more white matter inter-subject variability than those with subjective cognitive decline, or mild cognitive impairment. These white matter changes correlated significantly with blood-based biomarkers for Alzheimer disease, such as p-tau 217.

FDG-PET scans. These scans are not routine, but they are intended for research studies of pre-mild cognitive impairment patients. When pre-mild cognitive impairment and “non-decliner” control groups were compared in longitudinal studies of APOE-e4 carriers, the pre-mild cognitive impairment patients were shown to have lower baseline cerebral metabolic rates on FDG-PET scans in posterior cingulate gyri, bilateral parietal cortices, and left prefrontal cortex (16). FDG-PET, neuropsychology tests, and CSF biomarkers were examined from 85 amnestic mild cognitive impairment patients from the Alzheimer’s Disease Neuroimaging Initiative study cohort to see which would be the best predictors of conversion from mild cognitive impairment to Alzheimer dementia, and abnormalities on baseline FDG-PET (HR= 2.72) and an episodic memory test (HR=4.30) were demonstrated to be the best predictors of conversion (58). When stable mild cognitive impairment patients (n=46) were compared with those who progressed over time (n=33), the dynamic features of FDG-PET at baseline appeared to be the best predictors of progression, compared to the static features (114). In the pre-mild cognitive impairment FDG-PET study of Tondo and others, 105 participants (45%) had normal scans, whereas 58 (55%) showed evidence of hypometabolism (115). The most frequent abnormal pattern was frontal hypometabolism (28%), followed by an Alzheimer-like pattern (11%).

Amyloid PET scans. These scans have been used in identifying prodromal or mild Alzheimer patients in studies of antibody-based immunotherapies such as aducanumab, donanemab, and lecanemab (101; 89; 74; 118). Besides being useful as endpoint measures in clinical trials, amyloid PET scans are also useful predictors of disease progression. When preclinical Alzheimer patients with and without evidence of abnormal beta-amyloid PET were assessed and followed with cognitive tests, it was demonstrated that those with abnormal beta-amyloid were the ones who deteriorated cognitively over a 5- to 6-year period of time and eventually met criteria for dementia or mild cognitive impairment (27; 64; 48; 30). Jack and colleagues made the point that abnormal amyloid PET scans could be recorded in cognitively normal individuals, whereas that was never true of abnormal tau PET scans (51). Caprioglio and colleagues studied the psychological effects of disclosing positive results of amyloid-PET to patients who had subjective cognitive decline (mean age, 70 yrs; 52% male) (15). Although study partners were more likely than the patients to be distressed with news of positive test results, the patients themselves did not have significant increases in diagnoses of PTSD, severe anxiety, or severe depression. A similar study was performed by Hendriksen and others in patients with subjective cognitive decline (mean age, 66 yrs; 63% male) (41). Participants were largely satisfied with the information immediately provided about their scans. At 6 months, the amyloid positive patients had even more questions (45%) than the amyloid negative patients (12%). Negative emotions about the amyloid scans were rarely reported, regardless of the scan results.

Functional MRI. These scans are for research. The default mode network (measured by functional MRI) is active when people are daydreaming or not focused on the outside world. When 124 presymptomatic individuals with a family history of Alzheimer disease were studied with default mode network MRI imaging, higher connectivity between the medial temporal memory system and the rest of the brain was associated with better baseline memory, attention, and global cognition scores (119). Those 55% with subjective cognitive decline were found to be more likely to have an Alzheimer-like brain connectivity pattern.

Tau PET scans. These scans are used for research. In preclinical Alzheimer patients, increased uptake of the PET tracer F-18 flortaucipir in various regions of the brain was associated with worse performance on several cognitive tests at a stage when there was no apparent association between cognitive function and change in cortical thickness measures on MRI (87; 70). Jack and others pointed out that abnormal tau PET rarely occurred in the absence of abnormal amyloid PET, but that the reverse was common (51; 40). In their dynamic biomarker model of Alzheimer disease, amyloidosis was shown to develop first, then tauopathy appears later and was associated with the onset of clinical symptoms. Tau PET scans are useful in being able to distinguish the typical amnestic Alzheimer disease phenotypes from the atypical Alzheimer variants, such as posterior cortical atrophy and the logopenic variant of primary progressive aphasia (108; 120). In preclinical Alzheimer disease patients, the presence of tau deposition in the entorhinal cortex on tau-PET appears to mediate the association between novelty-related activity in the locus coeruleus and memory decline (93).

Management

Cognitive interventions. The theory behind cognitive training in those with pre-mild cognitive impairment or mild cognitive impairment is to prompt neuronal reorganization to meet the demands of new tasks, but the results of existing systematic reviews have been mixed. Sherman and colleagues conducted a meta-analysis of 26 randomized controlled trials published on this topic and showed that memory-based approaches were more successful than multidomain methods (105). The effect size measured in the Sherman study (Hedges g=0.39) was in the same range as that (g=0.36) reported in the meta-analysis of Mewborn and associates (71). Working memory interventions were also noted by Mewborn’s group to be the most effective (g=0.48). Cognitive training has been part of some multidomain intervention trials (83).

Continuous positive airway pressure (CPAP). If patients with pre-mild cognitive impairment have signs on polysomnography of sleep-disordered breathing, they are likely to benefit from CPAP. In a large prospective study of older adults with sleep-disordered breathing, CPAP was shown to significantly delay onset of mild cognitive impairment by about 10 years (86). Treating sleep apnea with CPAP also improves quality of life in those with predementia and dementia (85; 106).

Healthy lifestyle. Older at-risk participants in two large urban-based studies were followed for 5 to 6 years, and 20% to 25% developed incident Alzheimer dementia (26). Those who followed at least four elements of a healthy lifestyle (nonsmoking, moderate exercise for greater than 150 min/week, light-moderate alcohol use, high quality diet, sleeping for 7 to 9 hours per night, and engagement in cognitive activities) had at least a 60% reduction in risk of incident Alzheimer dementia.

Anti-amyloid therapies. There are now three anti-amyloid therapies that have been approved by the FDA for the treatment of patients with mild cognitive impairment and mild dementia: aducanumab (22), lecanemab (118), and donanemab (74). Aducanumab will be discontinued by its manufacturer as of November 1, 2024. (More information can be accessed at the following website: Alz.org). The cognitive treatment effects of these agents are small (lecanemab reduces disease progression by 27% over 18 months, compared to placebo), but all three approved drugs are effective at removing amyloid from the brain. The downside risk of lecanemab therapy was that 12.6% of treated patients developed a side effect known as amyloid related imaging abnormality - edema (ARIA-E) (118), somewhat less frequently than the 35.2% figure recorded in the aducanumab trials (22). Not all of these patients with ARIA-E were symptomatic, and most of the symptoms resolved with discontinuation of the drug. Simulation models have calculated that if anti-amyloid therapy is started in the pre-dementia stages, then it is possible for the patient to have an additional year to spend in the community, rather than in institutional care (77).

Outcomes

Nonsteroidal antiinflammatory drugs (NSAIDs). The hypothesis that NSAIDs might protect against the development of Alzheimer disease has been supported by a large number of cohort studies in older adults (42). There was a biologically plausible role for NSAIDs in pre-mild cognitive impairment because there is evidence for inflammatory activation in the early interaction of microglia and astrocytes with beta-amyloid and hyperphosphorylated tau. Nevertheless, Meyer and associates reported a negative result when they performed a 2-year, double-blind, placebo-controlled prevention trial examining the use of naproxen (vs. placebo) to slow the progression of disease in 195 presymptomatic Alzheimer disease patients (72). The primary outcome measure was rate of change on a multimodal presymptomatic Alzheimer Progression Score, which included tests of cognition, olfaction, hippocampal volume, and CSF levels of tau and beta-amyloid.

References

01: Agarwal P, Leurgans SE, Agrawal S, et al. Association of Mediterranean-DASH intervention for neurodegenerative delay and Mediterranean diets with Alzheimer disease pathology. Neurology 2023;100(22):e2259-68.** PMID 36889921
02: Alcolea D, Beeri MS, Rojas JC, et al. Blood biomarkers in neurodegenerative diseases. Neurology 2023;101(4):172-80.** PMID 36878698
03: Arenaza-Urquijo EM, Vemuri P. Resistance and resilience to Alzheimer disease: Clarifying terminology for preclinical studies. Neurology 2018;90(15):695-703. PMID 29592885
04: Au B, Dale-McGrath S, Tierney MC. Sex differences in the prevalence and incidence of mild cognitive impairment: a meta-analysis. Ageing Res Rev 2017;35:176-99. PMID 27771474
05: Banks WA, Reed MJ, Logsdon AF, Rhea EM, Erikson MA. Healthy aging and the blood-brain barrier. Nat Aging 2021;1(3):243-54. PMID 34368785
06: Baril AA, Beiser AS, Redline S, et al. Interleukin-6 interacts with sleep apnea severity when predicting incident Alzheimer’s disease dementia. J Alzheimers Dis 2021;79(4):1451-7. PMID 33459710
07: Barnes LL, Dhana K, Liu X, et al. Trial of the MIND diet for prevention of cognitive decline in older persons. N Engl J Med 2023;389(7):602-11. PMID 37466280
08: Bellenguez C, Kucukali F, Jansen IE, et al. New insights into the genetic etiology of Alzheimer disease and related dementias. Nat Genet 2022;54(4):412-36. PMID 35379992
09: Bilgel M, An Y, Helphrey J, et al. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain 2018;141(8):2475-85. PMID 29901697
10: Blumenthal JA, Smith PJ, Mabe S, et al. Lifestyle and neurocognition in older adults with cognitive impairments: A randomized trial. Neurology 2019;92(3):e212-23. PMID 30568005
11: Bocancea DI, Svenningsson AL, vanLoenhoud AC, et al. Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis. Brain 2023;146(9):3719-34. PMID 36967222
12: Buchman AS, Yu L, Wilson RS, et al. Physical activity, common brain pathologies, and cognition in community-dwelling older adults. Neurology 2019;92(8):e811-22. PMID 30651386
13: Burhanullah MH, Tschanz JT, Peters ME, et al. Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: The Cache County Study. Am J Gen Psychiatry 2019;28(1):64-71. PMID 31186157
14: Cannon-Albright LA, Foster NL, Schliep K, et al. Relative risk for Alzheimer disease based on complete family history. Neurology 2019;92(15):e1745-53. PMID 30867271
15: Caprioglio C, Ribaldi F, Visser LNC, et al. Analysis of psychological symptoms following disclosure of amyloid-positron emission tomography imaging results to adults with subjective cognitive decline. JAMA Netw Open 2023;6(1):e2250921. PMID 36637820
16: Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM. Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008;65(9):1231-6. PMID 18779428
17: Cavedo E, Lista S, Houot M, et al. Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology 2020;94:e30-e41. PMID 31801830
18: Chapman S, Renteria MA, Dworkin JD, et al. Association of subjective cognitive decline with progression to dementia in a cognitively unimpaired multiracial community sample. Neurology 2023;100(10):e1020-27. PMID 36450605
19: Chen G, Yang K, Du W, Hu X, Han Y. Clinical characteristics in subjective cognitive decline with and without worry: baseline investigation of the SILCODE study. J Alzheimers Dis 2019;72(2):443-54. PMID 31594226
20: Clouston SAP, Mann FD, Meliker J, et al. Incidence of dementia before age 65 years among World Trade Center attack responders. JAMA Netw Open 2024;7(6):e2416504. PMID 38865124
21: Creese B, Brooker H, Ismail Z, et al. Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. Am J Geriatr Psychiatry 2019;27(8):823-34. PMID 30902566
22: Day GS, Scarmeas N, Dubinsky R, et al. Aducanemab use in symptomatic Alzheimer disease evidence in focus: A report of the AAN Guidelines Subcommittee. Neurology 2022;98(15):619-31.** PMID 35197360
23: deBruijn RFA, Akoudad S, Cremers LGM, et al. Determinants, MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study. J Alzheimers Dis 2014;42(Suppl 3):S239-49.** PMID 24825566
24: Derby CA, Burns LC, Wang C, et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology 2013;80(14):1307-14. PMID 23468542
25: Di Lorito C, Bosco A, Booth V, Goldberg S, Harwood RH, Van der Wardt V. Adherence to exercise interventions in older people with mild cognitive impairment and dementia: a systematic review and meta-analysis. Prev Med Rep 2020;19:101139. PMID 32793408
26: Dhana K, Evans DA, Rajan KB, Bennett DA, Morris MC. Healthy lifestyle and the risk of Alzheimer dementia. Neurology 2020;95:e374-83.** PMID 32554763
27: Dubois B, Epelbaum S, Nyasse F, et al. Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-pre-AD): a longitudinal observational study. Lancet Neurol 2018;17(4):335-46. PMID 29500152
28: Edwin TH, Haberg AK, Zotcheva E, et al. Trajectories of occupational cognitive demands and risk of mild cognitive impairment and dementia in later life. Neurology 2024;102:e209353.** PMID 38630959
29: Erickson CM, Schultz SA, Oh JM, et al. KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD. Neurology 2019;92(16):e1878-89. PMID 30867273
30: Farrell ME, Thibault EG, Becker JA, et al. Spatial extent as a sensitive amyloid-PET metric in preclinical Alzheimer’s disease. Alzheimers Dement 2024;20(8):5434-49.** PMID 38988055
31: Foster NL, Bondi MW, Das R, et al. Quality improvement in neurology: mild cognitive impairment quality measurement set. Neurology 2019;93(16):1-9. PMID 31534026
32: Ganguli M, Lee C-W, Snitz BE, Hughes TF, McDade E, Chang CCH. Rates and risk factors for progression to incident dementia vary by age in a population cohort. Neurology 2015;84(1):72-80. PMID 25471390
33: Garrett SL, McDaniel D, Obideen M, et al. Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open 2019;2(12):e1917363. PMID 31834392
34: Ghahremani M, Wang M, Chen HY, et al. Plasma phosphorylated tau at threonine 181 and neuropsychiatric symptoms in preclinical and prodromal Alzheimer disease. Neurology 2023;100:e683-93. PMID 36323521
35: Gifford KA, Liu D, Hohman TJ, et al. A mutual self- and informant-report of cognitive complaint correlates with neuropathological outcomes in mild cognitive impairment. PLoS One 2015;10(11):e0141831. PMID 26539829
36: Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175(3):401-7. PMID 25621434
37: Groot C, van Loenhoud AC, Barkhof F, et al. Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology 2018;90(2):e149-56. PMID 29237798
38: Guyon A, Rousseau J, Begin FG, Bertin T, Lamothe G, Tremblay JP. Base editing strategy for insertion of the A673T mutation in the APP gene to prevent the development of AD in vitro. Mol Ther Nucleic Acids 2021;24:253-63. PMID 33815938
39: Haba-Rubio J, Marti-Soler H, Tobback N, et al. Sleep characteristics and cognitive impairment in the general population: The HypnoLaus Study. Neurology 2017;88(5):463-69. PMID 28039311
40: Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. JAMA Neurology 2019;76(8):915-24. PMID 31157827
41: Hendriksen HMA, deRijke TJ, Fruijtier A, et al. Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time. Alzheimers Dement 2024;20(9):6556-65. PMID 39087383
42: Hershey LA, Lipton RB. Naproxen for presymptomatic Alzheimer disease: Is this the end, or shall we try again? Neurology 2019;92(18):829-30. PMID 30952790
43: Hill NL, McDermott C, Mogle J, et al. Subjective cognitive impairment and quality of life. Int Psychogeriatr 2017;29(12):1965-77. PMID 28829003
44: Honig M, Altomare D, Caprioglio C, et al. Association between years of education and amyloid burden in patients with subjective cognitive decline, MCI, and Alzheimer disease. Neurology 2024;102:e208053. PMID 38377442
45: Hunt JFV, Vogt NM, Jonaitis EM, et al. Association of neighborhood context, cognitive decline, and cortical change in an unimpaired cohort. Neurology 2021;96(20):e2500-12.** PMID 33853894
46: Ingola S, De Boer C, Masselink LA, et al. Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimers Dement 2021;17(7):1189-204.** PMID 33811742
47: Insel PS, Mohlenhoff BS, Neylan TC, Krystal AD, Mackin RS. Association of sleep and beta-amyloid pathology among older cognitively unimpaired adults. JAMA (Netw Open) 2021;4(7):e2117573. PMID 34297074
48: Insel PS, Weiner M, Mackin RS, et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 2019;93(4):e322-33. PMID 31289148
49: Ismail Z, Aguera-Ortiz L, Brodaty H, et al. The mild behavioral impairment checklist (MBI-C): a rating scale for neuropsychiatric symptoms of pre-dementia populations. J Alzheimers Dis 2017;56(3):929-38. PMID 28059789
50: Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dem 2018;14(4):535-62.** PMID 29653606
51: Jack CR, Wiste HJ, Botha H, et al. The bivariate distribution of amyloid-beta and tau: relationship with established neurocognitive clinical syndromes. Brain 2019;142(10):3230-42. PMID 31501889
52: Janelidze S, Mattsson N, Stromrud E, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 2018;91(9):e867-77. PMID 30054439
53: Jia J, Ning Y, Chen M, et al. Biomarker changes during 20 years preceding Alzheimer’s disease. N Engl J Med 2024;390(8):712-22.** PMID 38381674
54: Ju YS, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol 2013;70(5):587-93. PMID 23479184
55: Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau 181 in the Alzheimer’s Disease Neuroimaging initiative. Mol Psychiatry 2021;26(2):429-42. PMID 33106600
56: Kulick ER, Wellenius GA, Boehme AK, et al. Long-term exposure to air pollution and trajectories of cognitive decline among older adults. Neurology 2020;94(17):e1782-92. PMID 32269113
57: Kulick ER, Wellenius GA, Kaufman JD, et al. Long-term exposure to ambient air pollution and subclinical cerebrovascular disease in NOMAS (the Northern Manhatten Study). Stroke 2017;48(7):1966-8. PMID 28455324
58: Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75(3):230-8. PMID 20592257
59: Largent EA, Grill JD, O’Brien K, Wolk D, Harkins K, Karlawish J. Testing for Alzheimer disease biomarkers and disclosing results across the disease continuum. Neurology 2023;100(21):1010-19.** PMID 36720642
60: Lewczuk P, Kornhuber J, German Dementia Competence Network, et al. Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer’s disease in pre-dementia subjects. J Alzheimers Dis 2015;48(2):433-41. PMID 26402007
61: Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396(10248):413-46.** PMID 32738937
62: Loessner L, Matthes C, Houssmann R, et al. Predictors of subjective cognitive deficits in patients with mild cognitive impairment. Psychogeriatrics 2022;22(2):210-17. PMID 34939254
63: Loewenstein DA, Greig MT, Schinka JA, et al. An investigation of pre-MCI: subtypes and longitudinal outcomes. Alzheimers Dement 2012 8(3):172-9. PMID 22546351
64: Lopez OL, Becker JT, Chang YF, et al. Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology 2018;90(21):e1920-28.** PMID 29695596
65: Lorenzini L, Collij LE, Tesi N, et al. Alzheimer’s disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non-demented individuals. Alzheimers Dement 2024;20(9):6146-60.** PMID 39073684
66: Machulda MM, Lundt ES, Albertson SM, et al. Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. Alzheimers Dement 2020;16(7):1013-22.** PMID 32418367
67: Mander BA, Winer JR, Walker MP. A restless night makes for a rising tide of amyloid. Brain 2017;140(8):2066-69. PMID 28899024
68: Manly JJ, Jones RN, Langa KM, et al. Estimating the prevalence of dementia and mild cognitive impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project. JAMA Neurol 2022;79(12):1242-49.** PMID 36279130
69: McGrath ER, Beiser AS, DeCarli C, et al. Blood pressure from mid- to late life and risk of incident dementia. Neurology 2017;89(24):2447-54. PMID 29117954
70: McSweeney M, Binette AP, Meyer P-F, et al. Intermediate flortaucipir uptake is associated with Abeta-PET and CSF tau in asymptomatic adults. Neurology 2020;94(11):e1190-200. PMID 32015176
71: Mewborn CM, Lindbergh CA, Stephen Miller L, et al. Cognitive interventions for cognitively healthy, mildly impaired, and mixed samples of older adults: a systematic review and meta-analysis of randomized-controlled trials. Neuropsychol Rev 2017;27(4):403-39. PMID 28726168
72: Meyer PF, Tremblay-Mercier J, Leoutsakos J, et al. INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. Neurology 2019;92(18):e2070-80. PMID 30952794
73: Michel P, Beaud V, Eskandari A, et al. Ischemic amnesia: causes and outcome. Stroke 2017;48(8):2270-73. PMID 28584000
74: Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med 2021;384(18):1691-704. PMID 33720637
75: Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand 2014;130(6):439-51. PMID 25219393
76: Molden J, Maxfield M. The impact of aging stereotypes on dementia worry. Eur J Ageing 2016;14(1):29-37. PMID 28804392
77: Monfared AAT, Ye W, Sardesai A, et al. A path to improved Alzheimer care: simulating long-term care outcomes of lecanemab in early Alzheimer’s disease from the CLARITY AD trial. Neurol Ther 2023;12(3):863-81. PMID 37009976
78: Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 2020;581(7806):71-6. PMID 32376954
79: Moore EE, Liu D, Li J, et al. Association of aortic stiffness with biomarkers of neuroinflammation, synaptic dysfunction, and neurodegeneration. Neurology 2021;97(4):e329-40. PMID 34031194
80: Morris JC, Schindler SE, McCue LM, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol 2019;76(3):264-73. PMID 30615028
81: Nation DA, Sweeney MD, Montagne A, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 2019;25(2):270-6. PMID 30643288
82: Ng TP, Feng L, Nyunt MSZ, et al. Metabolic syndrome and the risk of mild cognitive impairment and progression to dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort. JAMA Neurol 2016;73(4):456-63.** PMID 26926205
83: Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385(9984):2255-63.** PMID 25771249
84: Norby FL, Alonso A, Rooney MR, et al. Association of ventricular arrhythmias with dementia: the Atherosclerosis Risk in Communities (ARIC) study. Neurology 2021;96(6):e926-36. PMID 33106393
85: Ooms S, Ju YE. Treatment of sleep disorders in dementia. Curr Treat Options Neurol 2016;18(9):40. PMID 27476067
86: Osorio RS, Gumb T, Pirraglia E, et al. Sleep-disordered breathing advances cognitive decline in the elderly. Neurology 2015;84(19):1964-71. PMID 25878183
87: Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology 2019;92(6):e601-12. PMID 30626656
88: Palmqvist S, Stomrud E, Cullen N, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease. Alzheimer Dem 2022;19(4):1204-15.** PMID 35950735
89: Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid-beta immunotherapy for Alzheimer disease: is it now a long shot? Ann Neurol 2019;85(3):303-15. PMID 30635926
90: Panza GA, Taylor BA, MacDonald HV, et al. Can exercise improve cognitive symptoms of Alzheimer’s disease? J Am Geriatr Soc 2018;66(3):487-95. PMID 29363108
91: Pettigrew C, Nazarovs J, Soldan A, et al. Alzheimer disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal adults. Alzheimers Res Ther 2023;15(1):66. PMID 36978190
92: Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013;80(11):1048-56.** PMID 23390179
93: Prokopiou PC, Engels-Dominguez N, Schultz AP, et al. Association of novelty-related locus coeruleus function with entorhinal tau deposition and memory decline in preclinical Alzheimer disease. Neurology 2023;101(12):e1206-17. PMID 37491329
94: Qian J, Betensky RA, Hyman BT, Serrano-Ponzo A. Association of APOE genotype with heterogeneity of cognitive decline rate in Alzheimer disease. Neurology 2021;96(19):e2414-28. PMID 33771840
95: Rahman A, Schelbaum E, Hoffman K, et al. Sex-driven modifiers of Alzheimer risk: a multimodality brain imaging study. Neurology 2020;95(2):e166-78. PMID 32580974
96: Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139(9):1136-9. PMID 7114305
97: Reisberg B, Torossian C, Shulman MB, et al. Two-year outcomes, cognitive and behavioral markers of decline in healthy, cognitively normal older persons with global deterioration scale stage 2 (subjective cognitive decline with impairment). J Alzheimers Dis 2019;67(2):685-705. PMID 30689585
98: Roh HW, Chauhan N, Seo SW, et al. Assessing cognitive impairment and disability in older adults through the lens of whole brain white matter patterns. Alzheimers Dement (NY) 2024;20(9):6032-44.** PMID 39001624
99: Rostamzadeh A, Bohr L, Wagner M, Baethge C, Jessen F. Progression of subjective cognitive decline to MCI or dementia in relation to biomarkers for Alzheimer disease: a meta-analysis. Neurology 2022;99(17):e1866-74.** PMID 36028322
100: Schwartz HEM, Bay CP, McFeeley BM, Krivanek TJ, Daffner KR, Gale SA. The Brain Health Champion study: Health coaching changes behaviors in patients with cognitive impairment. Alzheimers Dement (NY) 2019;5:771-9. PMID 31763431
101: Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537(7618):50-6. PMID 27582220
102: Shao K, Hu X, Kleineidam L, et al. Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts. Alzheimers Dement (NY) 2024;20(9):5926-39. PMID 39072956
103: Sharma RA, Varga AW, Bubu OM, et al. Obstructive sleep apnea severity affects amyloid burden in cognitively normal elderly: a longitudinal study. Am J Respir Crit Care Med 2018;197(7)933-43. PMID 29125327
104: Sheikh F, Ismail Z, Mortby ME, et al. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. Int Psychogeriatr 2018;30(2):233-44. PMID 28879833
105: Sherman DS, Mauser J, Nuno M, Sherzai D. The efficacy of cognitive intervention in mild cognitive impairment (MCI): a meta-analysis of outcomes on neuropsychological measures. Neuropsychol Rev 2017;27(4):440-84. PMID 29282641
106: Shieu MM, Zaheed AB, Shannon C, et al. Positive airway pressure and cognitive disorders in adults with obstructive sleep apnea: A systematic review of the literature. Neurology 2022;99:e334-46.** PMID 35523585
107: Shinohara M, Ghani G, Hitomi J, Bu G, Sato N. APOE genotypes modify the obesity paradox in dementia. J Neurol Neurosurg Psychiatry 2023;94(9)670-80. PMID 37414536
108: Sintini I, Graff-Radford J, Senjem ML, et al. Longitudinal imaging biomarkers differ across Alzheimer’s disease phenotypes. Brain 2020;143(7):2281-94.** PMID 32572464
109: Soldan A, Pettigrew C, Fagan AM, et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology 2019;92(14):e1567-79. PMID 30842300
110: Steenland K, Goldstein FC, Levey A, Wharton W. A meta-analysis of Alzheimer’s disease incidence and prevalence comparing African Americans and Caucasians. J Alzheimers Dis 2016;50(1):71-6. PMID 26639973
111: Stites SD, Karlawish J, Harkins K, Rubright JD, Wolk D. Awareness of mild cognitive impairment and mild Alzheimer’s disease dementia diagnoses associated with lower self-ratings of quality of life in older adults. J Gerontol B Psychol Sci Soc Sci 2017;72(6):974-85. PMID 28958089
112: Stogmann E, Moser D, Klug S, et al. Activities of daily living and depressive symptoms in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s disease. J Alzheimers Dis 2016;49(4):1043-50. PMID 26577522
113: Tabatabaei-Jafari H, Walsh E, Shaw ME, Cherbuin N, Alzheimer's Disease Neuroimaging Initiative (ADNI). A simple and clinically relevant combination of neuroimaging and functional indexes for the identification of those at highest risk of Alzheimer disease. Neurobiol Aging 2018;69:102-10. PMID 29864716
114: Teng L, Li Y, Zhao Y, et al. Predicting MCI progression with FDG-PET and cognitive scores: A longitudinal study. BMC Neurology 2020;20:148. PMID 32316912
115: Tondo G, Boccalini C, Vanoli EG, et al. Brain metabolism and amyloid load in individuals with subjective cognitive decline or pre-mild cognitive impairment. Neurology 2022;99(3):e258-69. PMID 35487700
116: Urso D, Gnoni V, DeBlasi R, et al. Neuroimaging biomarkers in a patient with probable psychiatric-onset prodromal dementia with Lewy bodies. Neurology 2022;99(15):654-7. PMID 35953291
117: Van der Mussele S, Fransen E, Struyfs H, et al. Depression in mild cognitive impairment is associated with progression to Alzheimer’s disease: a longitudinal study. J Alzheimers Dis 2014;42(4):1239-50. PMID 25024328
118: Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. New Engl J Med 2022;388(1):9-21. PMID 36449413
119: Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, et al. Subjective cognitive decline is associated with altered default mode network connectivity in individuals with a family history of Alzheimer’s disease. Biol Psychiatry Cogn Neurosci Neuroimaging 2018;3(5):463-72. PMID 29735156
120: Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nature Med 2021;27(5):871-81.** PMID 33927414
121: Wang R, Laveskog A, Laukka EJ, et al. MRI load of cerebral microvascular lesions and neurodegeneration, cognitive decline, and dementia. Neurology 2018;91(16):e1487-97. PMID 30232255
122: Weigand AJ, Bondi MW, Thomas KR, et al. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology 2020;95(16):e2295-304.** PMID 32878992
123: Weuve J, Barnes LL, Mendes deLeon CF, et al. Cognitive aging in black and white Americans: cognition, cognitive decline, and incidence of Alzheimer disease dementia. Epidemiology 2018;29(1):151-9. PMID 28863046
124: Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: A randomized clinical trial. JAMA 2019;321(6):553-61.** PMID 30688979
125: Wilson DM 3rd, Cookson MR, Von den Bosch L, et al. Hallmarks of neurodegenerative diseases. Cell 2023;186(4):693-714. PMID 36803602
126: Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology 2020;95(9):e1134-43.** PMID 32636322
127: Wu A, Sharrett AR, Gottesman RF, et al. Association of brain magnetic resonance imaging signs with cognitive outcomes in persons with nonimpaired cognition and mild cognitive impairment. JAMA Netw Open 2019;2(5):e193359. PMID 31074810
128: Xu H, Garcia-Ptacek S, Trevisan M, et al. Kidney function, kidney function decline, and the risk of dementia in older adults: a registry-based study. Neurology 2021;96(24):e2956-65. PMID 33952656
129: Yang JJ, Keohane LM, Pan XF, et al. Association of healthy lifestyles with risk of Alzheimer disease and related dementias in low-income Black and White Americans. Neurology 2022;99(9):e944-53.** PMID 356697505
130: Yuan Y, Li J, Zhang N, et al. Body mass index and mild cognitive impairment among rural older adults in China: the moderating role of gender and age. BMC Psychiatry 2021;21(1):54. PMID 33485307
131: Zhu J, Ge F, Zeng Y, et al. Physical and mental activity, disease susceptibility, and risk of dementia: A prospective cohort study based on the UK biobank. Neurology 2022;99(8):e799-e813. PMID 35896434

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Linda A Hershey MD PhD FAAN FANA

Dr. Hershey of the University of Oklahoma Health Sciences Center has no relevant financial relationships to disclose.
See Profile
Dee Wu PhD

Dr. Wu of the University of Oklahoma Health Sciences Center has no relevant financial relationships to disclose.
See Profile

Editor

Howard S Kirshner MD

Dr. Kirshner of Vanderbilt University School of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Sergio Ramirez-Salazar MD
Dee Wu PhD

Patient Profile

Age range of presentation: 45 to 65+ years
Sex preponderance: Female = male
Heredity: Heredity may be a factor
Population groups selectively affected: No population group selectively affected
Occupation groups selectively affected: No occupation group selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Pre-mild cognitive impairment

Associated Disorders

sleep disorders
sleep-disordered breathing
psychiatric conditions
depression
hearing and visual loss
- anemia
- hepatic and renal failure
- ventricular arrhythmias

Differential Diagnosis

ischemic amnesia
other neurodegenerative diseases
dementia with Lewy bodies
vascular dementia
Parkinson disease
- use of anticholinergic medications
- transient global amnesia

Pre-mild cognitive impairment …

Pre-mild cognitive impairment

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Former Authors

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Metal neurotoxicity

Vascular cognitive impairment

Addictive disorders

Automatic-voluntary dissociation

Wilson disease

PART (Primary age-related tauopathy)

Anti-LGI1 encephalitis

Hypothyroidism

Pre-mild cognitive impairment

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

References

Contributors

Authors

Editor

Former Authors

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Metal neurotoxicity

Vascular cognitive impairment

Addictive disorders

Automatic-voluntary dissociation

Wilson disease

PART (Primary age-related tauopathy)

Anti-LGI1 encephalitis

Hypothyroidism

This is an article preview.
Start a Free Account
to access the full version.